0000899243-20-029694.txt : 20201029
0000899243-20-029694.hdr.sgml : 20201029
20201029165901
ACCESSION NUMBER: 0000899243-20-029694
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201027
FILED AS OF DATE: 20201029
DATE AS OF CHANGE: 20201029
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOTTSCHALK ADRIAN
CENTRAL INDEX KEY: 0001828724
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39634
FILM NUMBER: 201273422
MAIL ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: SUITE 610
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foghorn Therapeutics Inc.
CENTRAL INDEX KEY: 0001822462
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
STREET 2: SUITE 700
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-586-3100
MAIL ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
STREET 2: SUITE 700
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-27
0
0001822462
Foghorn Therapeutics Inc.
FHTX
0001828724
GOTTSCHALK ADRIAN
500 TECHNOLOGY SQUARE, STE 700
CAMBRIDGE
MA
02139
1
1
0
0
See Remarks
Common Stock
2020-10-27
4
C
0
25225
A
25225
I
See Footnote
Series A-2 Convertible Preferred Stock
2020-10-27
4
C
0
18018
D
Common Stock
18018
0
I
See Footnote
Series B Convertible Preferred Stock
2020-10-27
4
C
0
7207
D
Common Stock
7207
0
I
See Footnote
The Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020.
Shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee.
President & Chief Executive Officer
By: /s/ Allan Reine, M.D., Attorney-in-Fact
2020-10-29